Cargando…

Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes

OBJECTIVE: To evaluate the pharmacokinetics, pharmacodynamics, and safety of a novel U500 insulin aspart formulation (AT278 U500) compared with insulin aspart (IAsp U100). RESEARCH DESIGN AND METHODS: This single-center, randomized, double-blind study was conducted in 38 men with type 1 diabetes (bo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Svehlikova, Eva, Ashcroft, Nicole L., Gatschelhofer, Christina, Gerring, David, Höller, Vera, Jezek, Jan, Lackner, Bettina, Lawrence, Fiona, Pillai, Vijay, Ratzer, Maria, Urschitz, Martina, Wolf, Michael, Pieber, Thomas R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090892/ https://www.ncbi.nlm.nih.gov/pubmed/36710473 http://dx.doi.org/10.2337/dc22-1054

Ejemplares similares

Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes
por: Svehlikova, Eva, et al.
Publicado: (2021)

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial
por: Pieber, Thomas R., et al.
Publicado: (2023)

Fast‐acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose‐lowering effect compared with insulin aspart
por: Pieber, Thomas R., et al.
Publicado: (2019)

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes
por: Heise, Tim, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy
por: Kircheis, Gerald, et al.
Publicado: (2019)

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
por: Heise, T., et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2022)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)

Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences
por: Haahr, Hanne, et al.
Publicado: (2019)

Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
por: Liu, Hui, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study
por: García-García, Idrian, et al.
Publicado: (2010)

Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study
por: Hövelmann, Ulrike, et al.
Publicado: (2021)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

The association between anti‐insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in children and adolescents with type 1 diabetes
por: Biester, Torben, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen
por: Shin, Dongseong, et al.
Publicado: (2017)

Pharmacokinetic-Pharmacodynamic Model of Newly Developed Dexibuprofen Sustained Release Formulations
por: Muralidharan, Selvadurai
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics of Gliclazide from Immediate and Modified Release Formulation Tablets in Rats
por: Resztak, M, et al.
Publicado: (2014)

A Novel Microspheres Formulation of Puerarin: Pharmacokinetics Study and In Vivo Pharmacodynamics Evaluations
por: Song, Xiao, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
por: Saunthararajah, Y., et al.
Publicado: (2023)

Author Correction: Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
por: Liu, Hui, et al.
Publicado: (2021)

Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure
por: Drai, Roman V., et al.
Publicado: (2022)

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial
por: Kelleher, Dennis L., et al.
Publicado: (2012)

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen
por: Loisios-Konstantinidis, Ioannis, et al.
Publicado: (2020)

Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500
por: Bonifacio, Laura, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and Japan-approved NovoRapid in healthy Japanese subjects
por: Shiramoto, Masanari, et al.
Publicado: (2021)

Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers
por: Tacca, Mario Del, et al.
Publicado: (2013)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Effect of herbal formulation on glimepiride pharmacokinetics and pharmacodynamics in nicotinamide-streptozotocin-induced diabetic rats
por: Thikekar, Archana K., et al.
Publicado: (2022)

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
por: Landry, Ishani, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2022)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vtbaijhln17j21dfvg5qilb3oj